📋 Browse Articles

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧪 BiometalDB 🧬 Extraction
Filtered by: review ✕ clear all
🏷️ Tags (8587 usages)
⚗️ Metals 2487
▸ Metals — Platinum (109)
apoptosis (297)Pt (214)pt (24)ferroptosis (22)oxaliplatin (21)cisplatin (21)pyroptosis (7)necroptosis (6)transcription (6)carboplatin (5)transcription factors (5)transcriptional regulation (5)platinum (4)lead optimization (3)transcription regulation (3)metabolic adaptation (3)pt(ii) complexes (2)transcriptional regulatory interactions (2)ferroptosis induction (2)transcription initiation (2)transcription-coupled repair (2)adaptive binding (2)cellular adaptation (2)post-transcriptional regulation (2)pt(dach)methionine (1)transcription-coupled nucleotide excision repair (tc-ner) (1)triptolide (1)molecular optimization (1)pt(dach)cl4 (1)innate apoptotic immunity (1)pta (1)oligopeptides (1)transcription-coupled ner (1)ferroptosis suppressor protein 1 (fsp1) (1)apoptotic cells (1)platinumbased (1)hptab (1)signaling-transcriptional mechanisms (1)oncogene transcription inhibition (1)pt2 (1)admet optimization (1)receptor (1)pten (1)platinum(ii) (1)chain-of-thought prompt engineering (1)tetrapeptides (1)apoptotic function (1)adaptive immune response (1)gpt-2 (1)platinum drugs (1)ptii complex (1)platinum complexes (1)transcriptomics (1)cell metabolism disruption (1)peptide (1)pt(s,s-dab) (1)pt(r,r-dab) (1)pt3(hptab) (1)estrogen receptor (1)transcriptional addiction (1)transcription stress (1)septicemia (1)optical spectroscopies (1)receptors (1)selective serotonin reuptake inhibitors (ssri) (1)transcription-coupled nucleotide excision repair (1)pt(r,r-dach) (1)chiroptical response (1)diplatinum helicate (1)cyclometalated 1,3-bis(8-quinolyl) phenyl chloroplatinum(ii) (1)transcriptional activity (1)pt1 (1)disrupting a base pair (1)platinum-containing drugs (1)gpt-4 (1)transcriptional stalling (1)transcription inhibition (1)apoptotic (1)eukaryotic transcription (1)base pairing disruption (1)apoptosis-related disorders (1)coordination chemistry is not relevant, but bioinorganic and medicinal chemistry are related concepts (1)chatgpt (1)apoptosis induction (1)platinum(ii)-based (1)transcriptional activation (1)platinum-based compounds (1)inhibition of transcription factors (1)molecular descriptors (1)pt(dach)oxalato (1)polypeptide chains (1)pt(dach)cl2 (1)glp-1 receptor agonists (1)chiroptical applications (1)pt(s,s-dach) (1)cell-penetrating peptides (1)cysteine uptake (1)therapeutic optimization (1)shape description methods (1)transcription blockage (1)antiferroptotic (1)rna transcription (1)electronic absorption (1)cellular adaptation to hypoxia (1)ferroptosis suppressor protein 1 (1)apoptosis evasion (1)phosphopeptide-based kinome analysis (1)anti-apoptotic (1)gpt (1)
▸ Metals — Cobalt (185)
coordination-chemistry (102)Co (64)coordination chemistry (55)colorectal cancer (19)computational biology (7)spectroscopy (7)computational chemistry (6)computational modeling (6)pharmacology (6)co (5)pharmacovigilance (5)cryo-electron microscopy (4)glucose (4)colon cancer (4)metal complexes (4)glycolysis (4)oncology (4)pharmacokinetics (4)conformational change (3)glycocalyx (3)oncometabolite (3)complex i (3)oncosis (3)oncogenesis (2)polypharmacology (2)in-silico (2)plant secondary metabolites (2)computational approaches (2)in silico (2)convolutional neural networks (2)complex iii (2)natural compounds (2)pharmacodynamics (2)mitochondrial complex i (2)aerobic glycolysis (2)oncogene (2)covid-19 (2)microviscosity (1)pharmacometabolomics (1)complex formation (1)redox control (1)fatty alcohols (1)influence on physicochemical properties (1)fluorescence recovery after photobleaching (1)convolutional neural network (1)conditional lethality (1)picolinic acid (1)sars-cov-1 (1)metabolic control (1)pharmacological inhibition (1)pharmacokinetic (1)therapeutic controversy (1)multicolor emission (1)co2 fixation (1)protein complex (1)oncogenes (1)recombination (1)confocal microscopy (1)metal-ligand cooperation (1)cell surface recognition (1)sarcoma (1)network pharmacology (1)covalent interaction (1)escherichia coli (1)cobalamin (1)reversible compartmentalization (1)oncogene promoter regions (1)cellular compartments (1)coulometric karl fischer apparatus (1)combinatorial treatment (1)heme-containing enzymes (1)coimmunoprecipitation assay (1)glycosphingolipids (1)comorbidities (1)glycolytic activity (1)computational metabolomics (1)conformational isomerization (1)constitutive induction (1)confocal imaging (1)alcoholic hepatitis (1)knowledge discovery (1)oncogenic mutation (1)cobaltocene (1)coordination (1)computational approach (1)inorganic compounds (1)toxicology (1)conformational stability (1)connectivity mapping (1)mitochondrial uncoupling protein 2 (1)pharmacokinetic analyses (1)membrane permeability comparison (1)computer models (1)pathological conditions (1)dna condensation (1)4-octyl-itaconate (4-oi) (1)glucose dependence (1)cockayne's syndrome (1)atomic force microscope (1)complex diseases (1)dna conformational distortion (1)computational prediction (1)health economics (1)viscometry (1)conformational transitions (1)anticoagulant (1)glycome (1)oncogenic pathways (1)mitochondrial quality control (1)spin-orbit coupling (1)cytosolic ca21 concentration (1)cobamide (1)glycobiology (1)coimmunoprecipitation (1)dual protein expansion microscopy (1)brightfield microscopy (1)complexes (1)fluorescence recovery after photobleaching (frap) (1)glucose deprivation resistance (1)physicochemical properties (1)cell-like compartments (1)expansion microscopy (1)anticoagulants (1)ascorbic acid (1)oncogenic signaling (1)collective intelligence (1)cordycepin (1)genetic encoding (1)co2 (1)coupled-cluster computations (1)atp-competitive inhibitors (1)non-covalent interaction (1)computational methods (1)conformational states (1)conformational transition (1)electronic health records (1)sars-cov-2 (1)computational models (1)pharmacodynamic (1)text encoder (1)social cognition (1)sensory nerve conduction velocity (1)covalent binding (1)oncogene-mediated cellular transformation (1)fluorescence microscopy (1)glycolysis pathway (1)electronic conductometry (1)conformational landscapes (1)inductively coupled plasma mass spectrometry (1)itaconate (1)co(terpy)2+ (1)nmr spectroscopy (1)computational analysis (1)inductively coupled plasma mass spectrometer (1)coenzyme q10 (1)cell communication (1)colony formation assay (1)physico-chemical mechanisms (1)recognition (1)glycolytic enzymes (1)systems pharmacology (1)atomic force microscopy (1)computational methodologies (1)oncogenic (1)click expansion microscopy (1)glycosylation (1)n-(2-picolyl)salicylimine (1)ewing sarcoma (1)computational study (1)anticoagulation (1)confocal laser scanning microscopy (1)immuno-oncology (1)genome conformation profiling (1)somatic comorbidities (1)uv-vis spectroscopy (1)in silico analysis (1)co-immunoprecipitation (1)caco-2 cell monolayers (1)scoping review (1)conformational switch (1)damage recognition (1)entity recognition (1)energy conversion (1)noncovalent interactions (1)computer analysis (1)
▸ Metals — Iron (60)
▸ Metals — Ruthenium (86)
Ru (41)drug discovery (27)drug-delivery (23)drug resistance (11)prodrug (9)drug-drug interactions (9)drugs (7)adverse drug reactions (7)structural biology (7)drug repurposing (6)drug delivery (5)drug (5)drug development (5)g-quadruplex dna (4)ru (4)protein structure (3)drug interactions (3)structural analysis (3)drug screening (3)drug-target interaction prediction (3)g-quadruplex (3)drug design (3)drug repositioning (2)metallodrugs (2)structural data (2)drug-target interaction (2)serum (1)structure-based virtual screening (1)recruitment (1)hexammineruthenium(iii) (1)drug testing (1)spectrum diagrams (1)drug therapy (1)drug safety monitoring (1)drug sensitivity and resistance testing (1)drug safety assessment (1)structure (1)structural insights (1)adverse drug reaction detection (1)drug sensitization (1)drug target (1)truncations (1)drug-drug interaction prediction (1)protein structure-function relationship (1)pyruvate (1)drug-drug interaction identification (1)phenotypic drug screening (1)spontaneous adverse drug reaction reports (1)structural basis (1)antiviral drug discovery (1)drug tolerance (1)green rust (1)structural modeling (1)small-molecule drugs (1)structural methods (1)drug-nutrient interactions (1)adverse drug events (1)computational drug discovery (1)metal-based drugs (1)structural rearrangement (1)protein structure analysis (1)virus (1)small-molecule oral drugs (1)targeted drug delivery (1)adverse drug reaction (1)chemical drugs (1)doxorubicin (1)drug resistance reduction (1)drug-likeness (1)drug interaction prediction (1)drug target identification (1)macromolecular structure determination (1)resorufin (1)drug interaction analysis (1)drug combinations (1)non-steroidal anti-inflammatory drugs (nsaids) (1)structural bioinformatics (1)structure prediction (1)drug response (1)drug interaction screening (1)ruthenium(ii)-based (1)drug detection (1)structure-function analysis (1)metal-based drug (1)protocellular structures (1)drug interaction identification (1)
▸ Metals — Copper (63)
▸ Metals — Gold (19)
▸ Metals — Iridium (29)
▸ Metals — Others (17)
▸ Metals — Palladium (13)
▸ Metals — Zinc (5)
▸ Metals — Other (17)
🔬 Methods 1116
▸ Methods — Other experimental (213)
synthesis (244)ML (51)docking (23)natural language processing (12)in vitro (7)in vivo (6)morphological profiling (4)literature search (4)benchmarking (4)network analysis (4)image-based profiling (3)biochemical analysis (3)text analysis (3)bibliometric analysis (3)api (2)incites (2)vosviewer (2)experimental (2)theoretical studies (2)high-throughput screening (2)sequence analysis (2)information extraction (2)pubmed (2)cck-8 assay (2)statistics (2)lectin array (2)statistical approach (2)literature review (2)genetic (2)icite (2)lectin microarray (2)semantic search (2)data visualization (1)in vivo studies (1)target-based approaches (1)permeability measurement (1)gene expression profile (1)patch clamp (1)cnns (1)knockout mouse studies (1)cpg island methylator phenotype (1)in vitro models (1)immunoblot (1)bret2 (1)preclinical models (1)graph theory (1)gnns (1)passive rheology (1)nonequilibrium sensitivity analysis (1)ex vivo (1)multilayer network integration (1)inhibition assay (1)go analysis (1)experimental data analysis (1)caspase activity (1)nct (1)esm (1)web of science (1)gene expression microarray (1)uv light exposure (1)text2sql (1)decision-making (1)short tandem repeat profiling (1)in-vitro (1)analytical determination methods (1)perturbation (1)immunospecific antibodies (1)overexpression (1)mechanistic analysis (1)nuclease digestion (1)enzymatic reaction (1)excision assay (1)nuclear magnetic resonance (not explicitly mentioned but implied through study of variants) (1)pampa assay (1)experimental studies (1)null models (1)binding studies (1)clinical analysis (1)semi-supervised learning (1)efficacy analyses (1)supervised learning (1)electric field application (1)mouse model (1)estimates (1)isothermal calorimetry (1)rational design (1)learning to rank (1)gene expression analysis (1)fluorometry (1)octanol-aqueous shake-flask method (1)polypharmacy regimens (1)predictive models (1)xr-seq (1)graph learning (1)human studies (1)in vivo lung perfusion (1)merip-seq (1)uv-detection (1)atp hydrolysis (1)clinical methods (1)data processing (1)glovebox-bound apparatus (1)hoechst 33,258 staining (1)mutational analyses (1)semantic retrieval (1)solid-phase microextraction (1)immunization (1)pathscan array (1)quantitative phase behavior (1)natural bond orbital (nbo) analysis (1)ai (1)immunological analysis (1)cellular assays (1)synthetic biology tools (1)nanotherapeutic approaches (1)splicing regulation profiling (1)genome-wide screening (1)loss-of-function screens (1)histochemical staining (1)resazurin reduction assay (1)stopped-flow ph jump experiments (1)protein language model (1)experimental validation (1)matrix factorization (1)giao method (1)multi-head attention mechanism (1)rnns (1)phase ii trial (1)calorimetry (1)high throughput screening (1)trp emission (1)self-supervised learning (1)chemocentric approach (1)graph-based learning (1)tcga analysis (1)theoretical framework (1)machine-learning algorithms (1)ablation experiments (1)boolean logic (1)guanidine hydrochloride denaturation (1)ic50 index (1)statistical analysis (1)quantification (1)ensemble learning (1)in vitro study (1)relation search (1)relation extraction (1)image segmentation (1)genetic studies (1)genome-wide analysis (1)knockdown (1)ccsd(t) (1)biochemical characterization (1)performance evaluation (1)nbo 3.1 (1)rocplotter (1)mitoplast preparation (1)cryoem (1)entity annotation (1)modeling (1)systems engineering (1)database analysis (1)radiation exposure (1)prognostic tools (1)mouse models (1)nuclear magnetic resonance (1)proximity ligation assays (1)mp2(fc)/6–311 +  + (2d,2p) (1)personalized treatments (1)ncbi e-utilities (1)gradient boosting machines (1)kegg analysis (1)genetic algorithm (1)algorithms (1)experimental design (1)system-level/network analyses (1)visualized analysis (1)aimall (1)radiotherapy (1)laboratory methods (1)displacement assay (1)electrophoretic retardation measurements (1)seahorse platform (1)normoxia (1)mixture modeling (1)high-throughput (1)experimental methods (1)slot blot (1)magnetic tweezers (1)thermal denaturation (1)global genome ner (1)genetic profiling (1)mutation analysis (1)algorithm development (1)modelling (1)cell migration assay (1)methylome profiling (1)biochemical studies (1)patch clamping (1)umbrella review (1)zotero (1)immunoblotting (1)statistical methods (1)cellular models (1)miclip (1)fluorometric assay (1)enzymatic assays (1)genetic analysis (1)photophysical (1)biomedical information retrieval (1)logistic regression (1)in-vivo (1)mutational status analysis (1)
▸ Methods — Computational (31)
▸ Methods — Crystallography / Structure (4)
▸ Methods — Cell biology (21)
▸ Methods — Spectroscopy (19)
▸ Methods — Genomics / Omics (25)
▸ Methods — Mass spec / Chromatography (6)
▸ Methods — Clinical / Epidemiology (8)
▸ Methods — Electrochemistry (5)
▸ Methods — Other (1)
🎯 Targets 980
▸ Targets — Mitochondria (15)
▸ Targets — Other (157)
protein (58)enzyme (19)heme (11)gene expression (10)nucleus (9)genome (5)cardiolipin (5)enzymes (5)are (4)nucleolus (4)genetic variants (4)tfiih (4)lipids (4)signal transduction (4)cytoplasm (4)cellular metabolism (4)cell metabolism (3)cell surface (3)ribosome (3)metalloproteins (3)cells (3)cell (3)fumarate hydratase (2)dihydroorotate dehydrogenase (2)ubiquinone (2)stress response (2)tubulin (2)cytosol (2)polysulfides (2)cytochrome c oxidase (2)xpb (2)aif (2)genes (2)ribosome biogenesis (2)chromophore (1)none (1)substrates (1)clinical notes (1)acsl4 (1)protein phosphatase 2a (1)dpscs (1)albumin (1)tissues (1)trxr (1)substrate (1)platelet aggregation (1)tbk1 (1)metabolic phenotype (1)lab results (1)intracellular ph (1)sqr (1)cellular biochemistry (1)target (1)healthy cells (1)sting (1)gene targets (1)variants (1)three-way junction (1)heme-oxygenase1 (1)ddr1 (1)cajal bodies (1)target genes (1)upr (1)mif (1)heme a3 (1)nucleic acids (1)intracellular substrates (1)hydrogen sulfide (h2s) (1)mt1-mmp (1)gene (1)plasma proteins (1)adenine (1)metabolic signatures (1)nuclear foci (1)mscs (1)caspase cascade (1)p65 (1)dna synthesis (1)ddb2 (1)nuclear factor (1)hmga2 (1)ecm (1)diseases (1)spliceosomal proteins (1)neurons (1)smn protein (1)nadh/nad(p)h (1)rtk clusters (1)reactive species (1)metal (1)translation initiation (1)ligand (1)lipid droplet (1)metabolic enzymes (1)pkcd (1)protein kinases (1)peripheral nervous system (1)stem cells (1)cellular targets (1)metalloenzyme (1)chemical reactions (1)4ebp1 (1)procaspase 3 (1)ump synthase (1)rbx1 (1)literature-based evidence (1)ras (1)metabolic biomarkers (1)guanine (1)metal centers (1)ccr7 (1)cytochrome p450 2e1 (1)cell nucleus (1)lung tissue (1)ph (1)stress granules (1)erythrocytes (1)hexokinase 2 (1)nucleic acid (1)nitrogen species (1)four-way junction (1)nucleolar protein (1)p21 (1)mek1/2 (1)membrane potential (1)polysulfides (h2sn) (1)mek (1)annexin v (1)atp production (1)actin (1)traf5 (1)tme (1)cytoskeleton (1)proteoforms (1)cell cycle (1)p47phox (1)metabolome (1)cellular (1)aldoa (1)oxidants (1)zbp1 (1)cellular machines (1)atp (1)actin filaments (1)disease network (1)lipid damage (1)focal adhesions (1)p97 (1)protein sequence (1)xpc (1)whole cell (1)p38 (1)plectin (1)plasmids (1)propidium iodide (1)nadph oxidase 1 (nox1) (1)hdac enzymes (1)
▸ Targets — Nucleic acids (44)
▸ Targets — Membrane / Transport (15)
▸ Targets — Enzymes / Kinases (18)
▸ Targets — Transcription factors (5)
🦠 Diseases 880
▸ Diseases — Cancer (69)
▸ Diseases — Other (41)
▸ Diseases — Neurodegenerative (18)
▸ Diseases — Inflammatory / Immune (6)
▸ Diseases — Metabolic (5)
▸ Diseases — Cardiovascular (6)
▸ Diseases — Hepatic / Renal (8)
⚙️ Mechanisms 800
▸ Mechanisms — ROS / Redox (65)
▸ Mechanisms — Other (96)
cell cycle arrest (16)enzyme inhibition (12)phosphorylation (5)gene expression regulation (5)cell cycle regulation (4)persulfidation (3)detoxification (3)ligand dissociation (2)sequence variants (2)mechanism of action (2)resistance (2)inactivation (2)invasion inhibition (1)er stress responses (1)hormesis (1)invasiveness (1)epithelial-to-mesenchymal transition inhibition (1)oxygen-dependent metabolism (1)aquation (1)paracellular permeability (1)translation efficiency (1)denaturation (1)sequestration (1)oxidative post-translational modification (1)lipid metabolism (1)duplex unwinding (1)unfolded protein response (1)antioxidation (1)calcium regulation (1)radical formation (1)oxidative damage (1)splicing regulation (1)cell growth arrest (1)protein destabilization (1)multivalent interactions (1)protein phosphatase 2a modulation (1)protein dislocation (1)cell growth suppression (1)proteotoxic stress (1)protein rearrangements (1)p21 translation inhibition (1)gg-ner (1)pseudohypoxia (1)hypoxic response (1)electron shuttle (1)low-barrier hydrogen bond (1)kinase inhibition (1)synthetic lethality (1)stress responses (1)mutagenesis (1)subcellular relocalization (1)weak interactions (1)proton ejection (1)metabolic fuel selection (1)posttranslational modification (1)regulatory interactions (1)proton pumps (1)genetic regulation (1)protein unfolding (1)nucleolar homeostasis (1)ligand switch (1)ribosomopathies (1)oxidation-reduction (1)induced fit (1)localization (1)genetic mutation (1)mode of action (1)nucleolar stress response (1)cell killing capacity (1)ligand exchange (1)bond breaking (1)kinase activation (1)modulation (1)diadduct formation (1)cytoskeleton modulation (1)radical-mediated reaction (1)electron self-exchange (1)protein shuttling (1)pore formation (1)cellular metabolism regulation (1)nuclear export processes (1)ion selectivity (1)cell survival suppression (1)stabilization (1)cell damage (1)mitochondrial bioenergetics (1)gene therapy (1)cytochrome p450 2e1 inhibition (1)oxidative metabolic phenotype (1)phosphorylation regulation (1)aggregation (1)downregulation (1)glutamate exchange (1)acidosis (1)dysregulated gene expression (1)glycan expression (1)
▸ Mechanisms — Signaling (51)
▸ Mechanisms — Immune modulation (21)
▸ Mechanisms — DNA damage / Repair (5)
▸ Mechanisms — Epigenetic (18)
▸ Mechanisms — Cell death (7)
▸ Mechanisms — Protein interaction (14)
▸ Mechanisms — Metabolic rewiring (8)
🔗 Ligands 659
▸ Ligands — N-donor (25)
▸ Ligands — Heterocyclic (9)
▸ Ligands — C-donor / NHC (4)
▸ Ligands — S-donor (14)
▸ Ligands — O-donor (7)
▸ Ligands — Other (8)
▸ Ligands — P-donor (2)
▸ Ligands — Peptide / Protein (4)
▸ Ligands — Macrocyclic (3)
▸ Ligands — Polydentate (5)
🧠 Concepts 612
▸ Concepts — Other biomedical (178)
medicinal chemistry (122)photoactivated (27)cell biology (13)chemotherapy (11)metabolism (10)biochemistry (9)artificial intelligence (7)large language models (7)systems biology (6)information retrieval (5)precision medicine (5)gene regulation (5)data mining (5)chemoprevention (4)cheminformatics (4)therapeutic target (4)mitophagy (4)immunology (4)genetics (4)biomedical research (3)large language model (3)biomedical literature (3)hydrogen bonding (3)post-translational modifications (3)chemotherapy resistance (3)variant interpretation (3)immunometabolism (3)physiology (2)clinical practice (2)evidence extraction (2)biotransformation (2)metabolic regulation (2)physiological relevance (2)chemical biology (2)cell cycle progression (2)immunomodulation (2)biophysics (2)protein modification (2)biopharmaceutics (2)immunity (2)in vitro modeling (2)post-translational modification (2)targeted therapy (2)predictive modeling (2)therapy resistance (2)desiccant efficiency (1)multimodal data integration (1)stereochemistry (1)variant evaluation (1)epithelial-mesenchymal transition (1)metalloprotein (1)genetic screening (1)self-assembly (1)personalized therapy (1)protein function prediction (1)cellular mechanisms (1)protein targeting (1)evidence-based medicine (1)photophysics (1)protein modifications (1)translational research (1)paracellular transport (1)helicase mechanism (1)chemiosmosis (1)polarizability (1)nonequilibrium (1)genotype characterization (1)nuclear shape (1)nutrient dependency (1)metabolic engineering (1)interactome (1)therapies (1)probing (1)multiscale analysis (1)reactive species interactome (1)tissue-specific (1)pharmaceutics (1)knowledge extraction (1)metabolic activities (1)protein function (1)chemical ontology (1)proton delocalization (1)permeability (1)biomarkers (1)prediction tool (1)mechanisms of action (1)protein-ligand binding affinity prediction (1)short hydrogen bonds (1)chemical language models (1)biomedical informatics (1)organelle function (1)microbiome (1)pathogenesis (1)mechanistic framework (1)biosignatures (1)cellular stress response (1)ion-selective electrodes (1)multimodal fusion (1)gasotransmitter (1)carbon metabolism (1)bioengineering (1)ion association (1)enzyme mechanism (1)symmetry breaking (1)micropolarity (1)genome stability (1)scaffold (1)global health (1)clinical implications (1)cellular neurobiology (1)mesh indexing (1)llm (1)therapeutic strategy (1)ner (1)dissipative behavior (1)enzymology (1)pretrained model (1)longevity (1)profiling approaches (1)multimodal information integration (1)therapeutic implications (1)astrobiology (1)protein sequence analysis (1)selective degradation (1)mechanical properties (1)biomedical literature search (1)metabolism regulation (1)extracellular vesicles (1)protein chemistry (1)foundation model (1)data science (1)low-barrier hydrogen bonds (1)variant detection (1)synthetic biology (1)therapeutic innovation (1)therapeutic targeting (1)metabolic dependencies (1)protein data bank (1)cellular biology (1)phenotypic screening (1)immunoengineering (1)database (1)thermochemistry (1)therapeutic approaches (1)medical subject heading (1)network biology (1)inorganic chemistry (1)immunoregulation (1)ageing (1)protein interaction networks (1)hormone mimics (1)therapeutics (1)chemotherapy efficacy (1)metabolite-mediated regulation (1)regulatory landscape (1)chemical informatics (1)mental well-being (1)personalized medicine (1)cell plasticity (1)protein science (1)metabolic therapy (1)cell polarity (1)bioavailability (1)biomedicine (1)cellular stress (1)network medicine (1)energy transduction (1)boron helices (1)nucleolar biology (1)sialic acid (1)organic solvent drying (1)phenotypic analysis (1)in vivo perfusion (1)polypharmacy (1)hyperglycemia (1)phenotypic screens (1)mechanobiology (1)nuclear organization (1)
▸ Concepts — Bioinorganic (7)
▸ Concepts — Thermodynamics / Kinetics (10)
▸ Concepts — Evolution / Origin of life (9)
▸ Concepts — Nanomedicine / Delivery (2)
▸ Concepts — Cancer biology (1)
📦 Other 583
▸ Other (169)
review (375)proteins (11)cytochrome c (10)hydrogen sulfide (5)lactate (3)lipid (3)fumarate (3)kras (3)inhibitors (2)spermidine (2)csa (2)persulfides (2)xtb (2)catalase (2)csb (2)putrescine (2)metalloenzymes (2)mental health (1)carbonate ions (1)antithrombotic agents (1)pik3ca (1)butionine sulfoximine (1)prmt5 (1)uniprotkb (1)tpp-hclo4 (1)brequinar (1)pubtator 3.0 (1)metal salt (1)na-h2tcpp (1)nadhp (1)genotoxic agents (1)modular interaction motifs (1)npm1 protein (1)protons (1)ribosome biogenesis factors (1)nadh (1)ki-67 (1)chemistry (1)phosphatidic acid (1)heat shock proteins (1)l-ohp (1)brain (1)association study (1)ucp2 (1)alkaline phosphatase (1)trex1 (1)insp7 (1)ribosomal proteins (1)chebi (1)platelet aggregation inhibitors (1)artificial metalloenzymes (1)fluorescent probe (1)charge balancing (1)o-nitrophenyl octyl ether (1)dataset (1)resazurin (1)gfp (1)gap junctions (1)vitamin b12 (1)organic solutes (1)garlic oil (1)cationic surfactant (1)ligand charges (1)3-phenylquinazolinones (1)dodecyl-β-d-maltoside (1)r16 (1)bacterial anti-phage systems (1)uvssa (1)protein-templated synthesis (1)2-nitrophenyloctyl ether (1)atovaquone (1)tpp (1)p62 (1)ms023 (1)boron-doped helical systems (1)uv photoproducts (1)triton x-100 (1)tight binding (1)alkylating agents (1)bml284 (1)sodium azide (az) (1)phospholipids (1)mediator (1)snu13 (1)dithiothreitol (dtt) (1)cystine (1)proton pump inhibitors (1)mtt (1)adda 5 (1)rpa (1)ac220 (1)sodium decanoate (1)nad (1)lipophilic ionic additive (1)hdac inhibitor (1)methylene blue (1)greigite (1)sucralose (1)dspe-peg-2000 (1)bpep (1)phospholipid (1)diallyltrisulfide (1)pyrene (1)replication protein a (1)polynucleotide synthesis (1)eloxatine (1)drt (1)plasticity (1)nop56 (1)silicate (1)phosphoinositides (1)intrinsically disordered proteins (1)metoprolol (1)box c/d rnp (1)nop1 (1)dmf (1)diuretics (1)atp analogue (1)ribonuclease inhibitors (1)ligand properties (1)monoclonal antibodies (1)adp•bef3 (1)organic carbon (1)folfox-6 (1)desiccants (1)nadph (1)physical activity (1)minoxidil (1)hydrogel (1)st101 (1)pyrazino[2,3-d]pyridazine (1)tight-binding (1)rhea (1)cytochrome oxidase (1)astrocytes (1)decanol (1)elof1 (1)extended tight-binding (1)nucleophosmin (1)nsc49l (1)entinostat (1)insp6 (1)gsk-3β (1)mannosides (1)prmt1 inhibitor (1)lcs-1 (1)sleep quality (1)arginine (1)pp-insps (1)oligonucleotides (1)organic solvents (1)networks (1)bora[7]helicene (1)bardoxolone (1)insp8 (1)pluronic f-127 (1)probes (1)npm1 (1)pvc (1)heart aging (1)therapeutic agents (1)thapsigargin (1)brivudine (1)charge-balancing workflow (1)diborahelicate (1)folfox (1)pyp (1)tfiie (1)dpep (1)
🧬 Activities 402
▸ Activities — Catalytic / Sensing (15)
▸ Activities — Other biological (110)
inhibition (6)regulation (5)chemoresistance (5)therapeutic (4)oxidation (4)cell survival (4)cell growth (3)prediction (3)chemopreventive (2)target identification (2)phagocytosis (2)analysis (2)carcinogenesis (2)degradation (2)adr detection (2)treatment (2)cell viability (2)vesicle formation (2)cellular response (2)weight loss (2)therapy (2)survival (2)immunomodulatory (2)binding (2)neurotoxicity (2)photodynamic therapy (2)emission (1)incidence (1)protein degradation (1)protein expression (1)ribonuclease activity (1)therapeutic advances (1)protein interaction analysis (1)detection (1)protection (1)sulfide oxidase (1)model training (1)medication (1)diagnostic (1)toxicity (1)enzyme activity (1)transformation (1)physiological function (1)nitrification (1)data extraction (1)postmarketing surveillance (1)explanation (1)neuroprotection (1)functional regulators (1)prognosis (1)immunosuppression (1)signal production (1)personalized treatment (1)electron shuttling (1)morphological analysis (1)metabolic plasticity (1)myocardial ischemic injury (1)cell division (1)replication (1)nucleolar reorganization (1)multi-target (1)probe biology (1)promoting angiogenesis (1)oled (1)cell lysis (1)screening (1)carbon fixation (1)epigenome profiling (1)hypoxia alleviation (1)wound healing (1)question answering (1)ammonia oxidation (1)modulation of cytoskeleton (1)ppi prediction (1)cellular protection (1)gene function prediction (1)metabolic (1)cell invasion (1)cell line characterization (1)ddi screening (1)immunosuppressive (1)cellular transformation (1)profiling (1)tubulin inhibition (1)interactions (1)cell growth promotion (1)sensitization (1)mutation prevention (1)predictive biomarker (1)nucleolar stress (1)energy homeostasis (1)stimulation (1)carbon limitation response (1)stress regulation (1)cell migration (1)anti-ageing (1)regulatory assessment (1)prognostic value (1)evaluation (1)variant prioritization (1)induction (1)intracellular ph regulation (1)cell profiling (1)regulation of calcium levels (1)rare disease diagnosis (1)disease gene identification (1)therapeutic opportunities (1)invasion (1)metabolic activity (1)protein synthesis (1)
▸ Activities — Antimicrobial (3)
▸ Activities — Anticancer (3)
▸ Activities — Antioxidant / cytoprotect (2)

🔍 Filters

375 articles with selected tags
Jiang, Haowen , Li, Albert M. , Ye, Jiangbin · 2022 · Frontiers · Frontiers · added 2026-04-20
The term ‘magic bullet’ is a scientific concept proposed by the German Nobel laureate Paul Ehrlich in 1907, describing a medicine that could specifically and efficiently target a disease without harmi Show more
The term ‘magic bullet’ is a scientific concept proposed by the German Nobel laureate Paul Ehrlich in 1907, describing a medicine that could specifically and efficiently target a disease without harming the body. Oncologists have been looking for a magic bullet for cancer therapy ever since. However, the current therapies for cancers—including chemotherapy, radiation therapy, hormone therapy, and targeted therapy—pose either pan-cytotoxicity or only single-target efficacy, precluding their ability to function as a magic bullet. Intriguingly, niclosamide, an FDA-approved drug for treating tapeworm infections with an excellent safety profile, displays broad anti-cancer activity in a variety of contexts. In particular, niclosamide inhibits multiple oncogenic pathways such as Wnt/β-catenin, Ras, Stat3, Notch, E2F-Myc, NF-κB, and mTOR and activates tumor suppressor signaling pathways such as p53, PP2A, and AMPK. Moreover, niclosamide potentially improves immunotherapy by modulating pathways such as PD-1/PDL-1. We recently discovered that niclosamide ethanolamine (NEN) reprograms cellular metabolism through its uncoupler function, consequently remodeling the cellular epigenetic landscape to promote differentiation. Inspired by the promising results from the pre-clinical studies, several clinical trials are ongoing to assess the therapeutic effect of niclosamide in cancer patients. This current review summarizes the functions, mechanism of action, and potential applications of niclosamide in cancer therapy as a magic bullet. Show less
📄 PDF DOI: 10.3389/fonc.2022.1004978
Pd anticancer review
Emily L Que · 2022 · Current opinion in chemical biology · Elsevier · added 2026-04-20
no PDF DOI: 10.1016/j.cbpa.2022.102159
review
Laura Di Magno, Fiorella Di Pastena, Rosa Bordone +2 more · 2022 · Cancers · MDPI · added 2026-04-20
Biguanides are a family of antidiabetic drugs with documented anticancer properties in preclinical and clinical settings. Despite intensive investigation, how they exert their therapeutic effects is s Show more
Biguanides are a family of antidiabetic drugs with documented anticancer properties in preclinical and clinical settings. Despite intensive investigation, how they exert their therapeutic effects is still debated. Many studies support the hypothesis that biguanides inhibit mitochondrial complex I, inducing energy stress and activating compensatory responses mediated by energy sensors. However, a major concern related to this "complex" model is that the therapeutic concentrations of biguanides found in the blood and tissues are much lower than the doses required to inhibit complex I, suggesting the involvement of additional mechanisms. This comprehensive review illustrates the current knowledge of pharmacokinetics, receptors, sensors, intracellular alterations, and the mechanism of action of biguanides in diabetes and cancer. The conditions of usage and variables affecting the response to these drugs, the effect on the immune system and microbiota, as well as the results from the most relevant clinical trials in cancer are also discussed. Show less
no PDF DOI: 10.3390/cancers14133220
anticancer mitochondria review
Oluwafunke R Kolawole, Khosrow Kashfi · 2022 · International journal of molecular sciences · MDPI · added 2026-04-20
Acute inflammation or resolved inflammation is an adaptive host defense mechanism and is self-limiting, which returns the body to a state of homeostasis. However, unresolved, uncontrolled, or chronic Show more
Acute inflammation or resolved inflammation is an adaptive host defense mechanism and is self-limiting, which returns the body to a state of homeostasis. However, unresolved, uncontrolled, or chronic inflammation may lead to various maladies, including cancer. Important evidence that links inflammation and cancer is that nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, reduce the risk and mortality from many cancers. The fact that NSAIDs inhibit the eicosanoid pathway prompted mechanistic drug developmental work focusing on cyclooxygenase (COX) and its products. The increased prostaglandin E2 levels and the overexpression of COX-2 in the colon and many other cancers provided the rationale for clinical trials with COX-2 inhibitors for cancer prevention or treatment. However, NSAIDs do not require the presence of COX-2 to prevent cancer. In this review, we highlight the effects of NSAIDs and selective COX-2 inhibitors (COXIBs) on targets beyond COX-2 that have shown to be important against many cancers. Finally, we hone in on specialized pro-resolving mediators (SPMs) that are biosynthesized locally and, in a time, -dependent manner to promote the resolution of inflammation and subsequent tissue healing. Different classes of SPMs are reviewed, highlighting aspirin's potential in triggering the production of these resolution-promoting mediators (resolvins, lipoxins, protectins, and maresins), which show promise in inhibiting cancer growth and metastasis. Show less
no PDF DOI: 10.3390/ijms23031432
review
Danny Wu, Tao Tao, Emily A Eshraghian +3 more · 2022 · Frontiers in Oncology · Frontiers · added 2026-04-20
Extracellular RNA (exRNA) is a special form of RNA in the body. RNA carries information about genes and metabolic regulation in the body, which can reflect the real-time status of cells. This characte Show more
Extracellular RNA (exRNA) is a special form of RNA in the body. RNA carries information about genes and metabolic regulation in the body, which can reflect the real-time status of cells. This characteristic renders it a biomarker for disease diagnosis, treatment, and prognosis. ExRNA is transported through extracellular vesicles as a signal medium to mediate communication between cells. Tumor cells can release more vesicles than normal cells, thereby promoting tumor development. Depending on its easy detection, the advantages of non-invasive molecular diagnostic technology can be realized. In this systematic review, we present the types, vectors, and biological value of exRNA. We briefly describe new methods of tumor diagnosis and treatment, as well as the difficulties faced in the progress of such research. This review highlights the groundbreaking potential of exRNA as a clinical biomarker. Show less
📄 PDF DOI: 10.3389/fonc.2022.960072
review
Jiho Yoo · 2022 · BMB reports · added 2026-04-20
Mitochondria are cellular organelles that perform various functions within cells. They are responsible for ATP production, cell-signal regulation, autophagy, and cell apoptosis. Because the mitochondr Show more
Mitochondria are cellular organelles that perform various functions within cells. They are responsible for ATP production, cell-signal regulation, autophagy, and cell apoptosis. Because the mitochondrial proteins that perform these functions need Ca2+ ions for their activity, mitochondria have ion channels to selectively uptake Ca2+ ions from the cytoplasm. The ion channel known to play the most important role in the Ca2+ uptake in mitochondria is the mitochondrial calcium uniporter (MCU) holo-complex located in the inner mitochondrial membrane (IMM). This ion channel complex exists in the form of a complex consisting of the pore-forming protein through which the Ca2+ ions are transported into the mitochondrial matrix, and the auxiliary protein involved in regulating the activity of the Ca2+ uptake by the MCU holo-complex. Studies of this MCU holocomplex have long been conducted, but we didn't know in detail how mitochondria uptake Ca2+ ions through this ion channel complex or how the activity of this ion channel complex is regulated. Recently, the protein structure of the MCU holo-complex was identified, enabling the mechanism of Ca2+ uptake and its regulation by the MCU holo-complex to be confirmed. In this review, I will introduce the mechanism of action of the MCU holo-complex at the molecular level based on the Cryo-EM structure of the MCU holo-complex to help understand how mitochondria uptake the necessary Ca2+ ions through the MCU holo-complex and how these Ca2+ uptake mechanisms are regulated. [BMB Reports 2022; 55(11): 528-534]. Show less
no PDF DOI: 10.5483/BMBRep.2022.55.11.134
amino-acid mitochondria review
Tania Gamberi, Giovanni Chiappetta, Tania Fiaschi +3 more · 2022 · Medicinal Research Reviews · Wiley · added 2026-04-20
AbstractAuranofin is an oral gold(I) compound, initially developed for the treatment of rheumatoid arthritis. Currently, Auranofin is under investigation for oncological application within a drug repu Show more
AbstractAuranofin is an oral gold(I) compound, initially developed for the treatment of rheumatoid arthritis. Currently, Auranofin is under investigation for oncological application within a drug repurposing plan due to the relevant antineoplastic activity observed both in vitro and in vivo tumor models. In this review, we analysed studies in which Auranofin was used as a single drug or in combination with other molecules to enhance their anticancer activity or to overcome chemoresistance. The analysis of different targets/pathways affected by this drug in different cancer types has allowed us to highlight several interesting targets and effects of Auranofin besides the already well‐known inhibition of thioredoxin reductase. Among these targets, inhibitory‐κB kinase, deubiquitinates, protein kinase C iota have been frequently suggested. To rationalize the effects of Auranofin by a system biology‐like approach, we exploited transcriptomic data obtained from a wide range of cell models, extrapolating the data deposited in the Connectivity Maps website and we attempted to provide a general conclusion and discussed the major points that need further investigation. Show less
no PDF DOI: 10.1002/med.21872
Au amino-acid anticancer review
Linchong Sun, Huafeng Zhang, Ping Gao · 2022 · Protein & cell · Springer · added 2026-04-20
Metabolic rewiring and epigenetic remodeling, which are closely linked and reciprocally regulate each other, are among the well-known cancer hallmarks. Recent evidence suggests that many metabolites s Show more
Metabolic rewiring and epigenetic remodeling, which are closely linked and reciprocally regulate each other, are among the well-known cancer hallmarks. Recent evidence suggests that many metabolites serve as substrates or cofactors of chromatin-modifying enzymes as a consequence of the translocation or spatial regionalization of enzymes or metabolites. Various metabolic alterations and epigenetic modifications also reportedly drive immune escape or impede immunosurveillance within certain contexts, playing important roles in tumor progression. In this review, we focus on how metabolic reprogramming of tumor cells and immune cells reshapes epigenetic alterations, in particular the acetylation and methylation of histone proteins and DNA. We also discuss other eminent metabolic modifications such as, succinylation, hydroxybutyrylation, and lactylation, and update the current advances in metabolism- and epigenetic modification-based therapeutic prospects in cancer. Show less
📄 PDF DOI: 10.1007/s13238-021-00846-7
amino-acid review
Li S, Lu Z, Sun R +4 more · 2022 · Cancers · MDPI · added 2026-04-20
Li S, Lu Z, Sun R, Guo S, Gao F, Cao B, Aa J Show less
SLC7A11 controls the uptake of extracellular cystine in exchange for glutamate at a ratio of 1:1, and it is overexpressed in a variety of tumours. Accumulating evidence has shown that the expression o Show more
SLC7A11 controls the uptake of extracellular cystine in exchange for glutamate at a ratio of 1:1, and it is overexpressed in a variety of tumours. Accumulating evidence has shown that the expression of SLC7A11 is fine-tuned at multiple levels, and plays diverse functional and pharmacological roles in tumours, such as cellular redox homeostasis, cell growth and death, and cell metabolism. Many reports have suggested that the inhibition of SLC7A11 expression and activity is favourable for tumour therapy; thus, SLC7A11 is regarded as a potential therapeutic target. However, emerging evidence also suggests that on some occasions, the inhibition of SLC7A11 is beneficial to the survival of cancer cells, and confers the development of drug resistance. In this review, we first briefly introduce the biological properties of SLC7A11, including its structure and physiological functions, and further summarise its regulatory network and potential regulators. Then, focusing on its role in cancer, we describe the relationships of SLC7A11 with tumourigenesis, survival, proliferation, metastasis, and therapeutic resistance in more detail. Finally, since SLC7A11 has been linked to cancer through multiple approaches, we propose that its contribution and regulatory mechanism require further elucidation. Thus, more personalised therapeutic strategies should be adapted when targeting SLC7A11. Show less
📄 PDF DOI: 10.3390/cancers14133059
review
Jyotsana N, Ta KT, DelGiorno KE · 2022 · Frontiers in Oncology · Frontiers · added 2026-04-20
SLC7A11/xCT is an antiporter that mediates the uptake of extracellular cystine in exchange for glutamate. Cystine is reduced to cysteine, which is a rate-limiting precursor in glutathione synthesis; a Show more
SLC7A11/xCT is an antiporter that mediates the uptake of extracellular cystine in exchange for glutamate. Cystine is reduced to cysteine, which is a rate-limiting precursor in glutathione synthesis; a process that protects cells from oxidative stress and is, therefore, critical to cell growth, proliferation, and metabolism. SLC7A11 is expressed in different tissues and plays diverse functional roles in the pathophysiology of various diseases, including cancer, by regulating the processes of redox homeostasis, metabolic flexibility/nutrient dependency, immune system function, and ferroptosis. SLC7A11 expression is associated with poor prognosis and drug resistance in cancer and, therefore, represents an important therapeutic target. In this review, we discuss the molecular functions of SLC7A11 in normal versus diseased tissues, with a special focus on how it regulates gastrointestinal cancers. Further, we summarize current therapeutic strategies targeting SLC7A11 as well as novel avenues for treatment. Show less
📄 PDF DOI: 10.3389/fonc.2022.858462
Fe ROS review synthesis
S. Trapotsi, G. Drakakis, A. Koutsoukas +1688 more · 2022 · RSC Chemical Biology · Royal Society of Chemistry · added 2026-04-20
S. Trapotsi, G. Drakakis, A. Koutsoukas, I. Cortes–Ciriano, P. Martínez–Alonso, T. E. Malliavin, A. Velazquez-Campoy, S. C. Brewerton, M. J. Bodkin, D. A. Evans, R. C. Glen, J. A. Carrodeguas, A. Bender, S. W. Page, J. E. Maddison, M. R. Trusheim, E. R. Berndt, F. L. Douglas, L. Rovin, C. J. Bailey, G. Zhou, R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M. F. Hirshman, L. J. Goodyear, D. E. Moller, I. Bezprozvanny, J. Wu, Q. Li, A. C. Lai, C. M. Crews, J. Downward, F. Ardito, M. Giuliani, D. Perrone, G. Troiano, L. L. Muzio, H. Lodish, A. Berk, S. L. Zipursky, P. Matsudaira, D. Baltimore, J. Darnell, N. Ammeux, B. E. Housden, A. Georgiadis, Y. Hu, N. Perrimon, J. E. Dumont, S. Dremier, I. Pirson, C. Maenhaut, T. Vu, F. X. Claret, H. S. Camp, O. Li, S. C. Wise, Y. H. Hong, C. L. Frankowski, R. Vanbogelen, T. Leff, K. Kores, J. Konc, U. Bren, M.-A. Trapotsi, L. H. Mervin, A. M. Afzal, N. Sturm, O. Engkvist, I. P. Barrett, B. Baillif, J. Wichard, O. Méndez-Lucio, D. Rouquié, J. Inglese, D. S. Auld, B. A. Wetmore, J. F. Wambaugh, S. S. Ferguson, M. A. Sochaski, D. M. Rotroff, K. Freeman, H. J. Clewell III, D. J. Dix, M. E. Andersen, K. A. Houck, B. Allen, R. S. Judson, R. Singh, R. J. Kavlock, A. M. Richard, R. S. Thomas, M. Schenone, V. Dančík, B. K. Wagner, P. A. Clemons, A. Subramanian, R. Narayan, S. M. Corsello, D. D. Peck, T. E. Natoli, X. Lu, J. Gould, J. F. Davis, A. A. Tubelli, J. K. Asiedu, D. L. Lahr, J. E. Hirschman, Z. Liu, M. Donahue, B. Julian, M. Khan, D. Wadden, I. C. Smith, D. Lam, A. Liberzon, C. Toder, M. Bagul, M. Orzechowski, O. M. Enache, F. Piccioni, S. A. Johnson, N. J. Lyons, A. H. Berger, A. F. Shamji, A. N. Brooks, A. Vrcic, C. Flynn, J. Rosains, D. Y. Takeda, R. Hu, D. Davison, J. Lamb, K. Ardlie, L. Hogstrom, P. Greenside, N. S. Gray, S. Silver, X. Wu, W.-N. Zhao, W. Read-Button, S. J. Haggarty, L. V. Ronco, J. S. Boehm, S. L. Schreiber, J. G. Doench, J. A. Bittker, D. E. Root, B. Wong, T. R. Golub, J. M. Raser, E. K. O’Shea, A. A. Kalaitzis, N. D. Lawrence, D. P. Nusinow, J. Szpyt, M. Ghandi, C. M. Rose, E. R. McDonald, M. Kalocsay, J. Jané-Valbuena, E. Gelfand, D. K. Schweppe, M. Jedrychowski, J. Golji, D. A. Porter, T. Rejtar, Y. K. Wang, G. V. Kryukov, F. Stegmeier, B. K. Erickson, L. A. Garraway, W. R. Sellers, S. P. Gygi, M.-A. Bray, S. Singh, H. Han, C. T. Davis, B. Borgeson, C. Hartland, M. Kost-Alimova, S. M. Gustafsdottir, C. C. Gibson, A. E. Carpenter, A. X. Lu, O. Z. Kraus, S. Cooper, A. M. Moses, S. N. Chandrasekaran, H. Ceulemans, J. D. Boyd, M. J. Cox, S. Jaensch, J. Van de Waeter, L. Cougnaud, D. Seynaeve, S. Benalla, S. J. Koo, I. Van Den Wyngaert, J.-M. Neefs, D. Malkov, M. Bittremieux, M. Steemans, P. J. Peeters, J. K. Wegner, E. Gustin, Y. T. Chong, H. W. H. Göhlmann, I. Nassiri, M. N. McCall, P. D. Piehowski, V. A. Petyuk, D. J. Orton, F. Xie, M. Ramirez-Restrepo, A. Engel, A. P. Lieberman, R. L. Albin, D. G. Camp, R. D. Smith, A. J. Myers, M. Medo, D. M. Aebersold, M. Medová, C. H. Johnson, F. J. Gonzalez, T. Ramirez, M. Daneshian, H. Kamp, F. Y. Bois, M. R. Clench, M. Coen, B. Donley, S. M. Fischer, D. R. Ekman, E. Fabian, C. Guillou, J. Heuer, H. T. Hogberg, H. Jungnickel, H. C. Keun, G. Krennrich, E. Krupp, A. Luch, F. Noor, E. Peter, B. Riefke, M. Seymour, N. Skinner, L. Smirnova, E. Verheij, S. Wagner, T. Hartung, B. van Ravenzwaay, M. Leist, A. M. D. Livera, M. Sysi-Aho, L. Jacob, J. A. Gagnon-Bartsch, S. Castillo, J. A. Simpson, T. P. Speed, R. Chaleckis, I. Meister, P. Zhang, C. E. Wheelock, J. G. Abelin, J. Patel, C. M. Feeney, L. Fagbami, A. L. Creech, L. Pino, J. W. Qiao, E. Kuhn, A. Officer, J. Li, S. Abbatiello, R. Sidman, E. Snyder, S. A. Carr, J. D. Jaffe, Y. A. Chen, S. A. Eschrich, L. Litichevskiy, R. Peckner, C. M. Dunning, J. D. Egertson, S. Egri, T. Ko, B. X. MacLean, A. E. Mungenast, M. Papanastasiou, V. Sharma, J. Z. Young, M. J. MacCoss, L.-H. Tsai, R. Lewis, Z. Tanoli, U. Seemab, A. Scherer, K. Wennerberg, J. Tang, M. Vähä-Koskela, A. Gaulton, L. J. Bellis, A. P. Bento, J. Chambers, M. Davies, A. Hersey, Y. Light, S. McGlinchey, D. Michalovich, B. Al-Lazikani, J. P. Overington, S. Kim, J. Chen, T. Cheng, A. Gindulyte, J. He, S. He, B. A. Shoemaker, P. A. Thiessen, B. Yu, L. Zaslavsky, J. Zhang, E. E. Bolton, I. A. Smit, C. H. G. Allen, F. Svensson, T. Hanser, J. Bajorath, J. Sun, N. Jeliazkova, V. Chupakhin, J.-F. Golib-Dzib, L. Carlsson, J. Wegner, I. Georgiev, V. Jeliazkov, N. Kochev, T. J. Ashby, H. Chen, T. Kalliokoski, C. Kramer, A. Vulpetti, P. Gedeck, A. Lin, D. Horvath, V. Afonina, G. Marcou, J.-L. Reymond, A. Varnek, C. Ye, D. J. Ho, M. Neri, C. Yang, T. Kulkarni, R. Randhawa, M. Henault, N. Mostacci, P. Farmer, S. Renner, R. Ihry, L. Mansur, C. G. Keller, G. McAllister, M. Hild, J. Jenkins, A. Kaykas, P. R. Bushel, R. S. Paules, S. S. Auerbach, H. K. Yalamanchili, Y.-W. Wan, G. X. Y. Zheng, J. M. Terry, P. Belgrader, P. Ryvkin, Z. W. Bent, R. Wilson, S. B. Ziraldo, T. D. Wheeler, G. P. McDermott, J. Zhu, M. T. Gregory, J. Shuga, L. Montesclaros, J. G. Underwood, D. A. Masquelier, S. Y. Nishimura, M. Schnall-Levin, P. W. Wyatt, C. M. Hindson, R. Bharadwaj, A. Wong, K. D. Ness, L. W. Beppu, H. J. Deeg, C. McFarland, K. R. Loeb, W. J. Valente, N. G. Ericson, E. A. Stevens, J. P. Radich, T. S. Mikkelsen, B. J. Hindson, J. H. Bielas, N. J. Schurch, P. Schofield, M. Gierliński, C. Cole, A. Sherstnev, V. Singh, N. Wrobel, K. Gharbi, G. G. Simpson, T. Owen-Hughes, M. Blaxter, G. J. Barton, A. Koussounadis, S. P. Langdon, I. H. Um, D. J. Harrison, V. A. Smith, X. Xie, E. D. Crawford, D. Peck, J. W. Modell, I. C. Blat, M. J. Wrobel, J. Lerner, J.-P. Brunet, K. N. Ross, M. Reich, H. Hieronymus, G. Wei, S. A. Armstrong, R. Wei, E. S. Lander, R. Edgar, M. Domrachev, A. E. Lash, H. Parkinson, M. Kapushesky, M. Shojatalab, N. Abeygunawardena, R. Coulson, A. Farne, E. Holloway, N. Kolesnykov, P. Lilja, M. Lukk, R. Mani, T. Rayner, A. Sharma, E. William, U. Sarkans, A. Brazma, D. L. Svoboda, T. Saddler, Y. Igarashi, N. Nakatsu, T. Yamashita, A. Ono, Y. Ohno, T. Urushidani, H. Yamada, N. Lim, P. Pavlidis, A. Musa, L. S. Ghoraie, S.-D. Zhang, G. Galzko, O. Yli-Harja, M. Dehmer, B. Haibe-Kains, F. Emmert-Streib, M. Bickle, S. Seal, H. Yang, L. Vollmers, T. R. Jones, M. R. Lamprecht, C. Clarke, I. H. Kang, O. Friman, D. A. Guertin, J. H. Chang, R. A. Lindquist, J. Moffat, P. Golland, D. M. Sabatini, M. Held, M. H. A. Schmitz, B. Fischer, T. Walter, B. Neumann, M. H. Olma, M. Peter, J. Ellenberg, D. W. Gerlich, S. Rajaram, B. Pavie, L. F. Wu, S. J. Altschuler, J. Ollion, J. Cochennec, F. Loll, C. Escudé, T. Boudier, T. Wollmann, M. Gunkel, I. Chung, H. Erfle, K. Rippe, K. Rohr, J. C. Caicedo, A. Goodman, K. W. Karhohs, B. A. Cimini, J. Ackerman, M. Haghighi, C. Heng, T. Becker, M. Doan, C. McQuin, M. Rohban, V. Chernyshev, L. Kamentsky, L. Ding, S. M. Rafelski, D. Thirstrup, W. Wiegraebe, F. Heigwer, S. Warchal, P. Qiu, C. Molnar, A. S. Vasilevich, J. D. Barry, H. S. Bansal, O. Kraus, M. Wawer, L. Paavolainen, M. D. Herrmann, J. Hung, H. Hennig, J. Concannon, I. Smith, P. Rees, P. Horvath, R. G. Linington, V. Ljosa, K. L. Sokolnicki, E. Williams, J. Moore, S. W. Li, G. Rustici, A. Tarkowska, A. Chessel, S. Leo, B. Antal, R. K. Ferguson, R. E. C. Salas, J. R. Swedlow, M. H. Rohban, N. E. Bodycombe, T. P. Hasaka, C. S. Hon, M. M. Kemp, K. Li, D. Walpita, M. J. Wawer, A. Mullard, A. A. Saei, C. M. Beusch, A. Chernobrovkin, P. Sabatier, B. Zhang, Ü. G. Tokat, E. Stergiou, M. Gaetani, Á. Végvári, R. A. Zubarev, M. Zapalska-Sozoniuk, L. Chrobak, K. Kowalczyk, M. Kankofer, H. Gullberg, K. Johansson, B. Lundgren, P. I. Arvidsson, E. S. J. Arnér, Y. Perez-Riverol, A. Csordas, J. Bai, M. Bernal-Llinares, S. Hewapathirana, D. J. Kundu, A. Inuganti, J. Griss, G. Mayer, M. Eisenacher, E. Pérez, J. Uszkoreit, J. Pfeuffer, T. Sachsenberg, Ş. Yılmaz, S. Tiwary, J. Cox, E. Audain, M. Walzer, A. F. Jarnuczak, T. Ternent, J. A. Vizcaíno, P. Samaras, T. Schmidt, M. Frejno, S. Gessulat, M. Reinecke, A. Jarzab, J. Zecha, J. Mergner, P. Giansanti, H.-C. Ehrlich, S. Aiche, J. Rank, H. Kienegger, H. Krcmar, B. Kuster, M. Wilhelm, B. Aslam, M. Basit, M. A. Nisar, M. Khurshid, M. H. Rasool, Y. Lao, X. Wang, N. Xu, H. Zhang, H. Xu, K. Hollywood, D. R. Brison, R. Goodacre, L. Zhang, C. Ma, H. Chao, Y. Long, Z. Li, X. Ge, H. Xia, Y. Yin, J. Batley, M. Li, R. Cavill, D. Jennen, J. Kleinjans, J. J. Briedé, W. Lu, X. Su, M. S. Klein, I. A. Lewis, O. Fiehn, J. D. Rabinowitz, M. Wright Muelas, I. Roberts, F. Mughal, S. O’Hagan, P. J. Day, D. B. Kell, Y. Lin, G. W. Caldwell, W. Lang, J. Masucci, K. Peters, J. Bradbury, S. Bergmann, M. Capuccini, M. Cascante, P. de Atauri, T. M. D. Ebbels, C. Foguet, R. Glen, A. Gonzalez-Beltran, U. L. Günther, E. Handakas, T. Hankemeier, K. Haug, S. Herman, P. Holub, M. Izzo, D. Jacob, D. Johnson, F. Jourdan, N. Kale, I. Karaman, B. Khalili, P. Emami Khonsari, K. Kultima, S. Lampa, A. Larsson, C. Ludwig, P. Moreno, S. Neumann, J. A. Novella, C. O’Donovan, J. T. M. Pearce, A. Peluso, M. E. Piras, L. Pireddu, M. A. C. Reed, P. Rocca-Serra, P. Roger, A. Rosato, R. Rueedi, C. Ruttkies, N. Sadawi, R. M. Salek, S.-A. Sansone, V. Selivanov, O. Spjuth, D. Schober, E. A. Thévenot, M. Tomasoni, M. van Rijswijk, M. van Vliet, M. R. Viant, R. J. M. Weber, G. Zanetti, C. Steinbeck, J. Xia, N. Psychogios, N. Young, D. S. Wishart, K. Cochrane, V. C. Nainala, M. Williams, J. Chang, K. V. Jayaseelan, A. I. Campos, M. Zampieri, T. Fuhrer, D. C. Sévin, U. Sauer, N. Zamboni, N. J. Shah, S. Sureshkumar, D. G. Shewade, P. V. Hornbeck, J. M. Kornhauser, S. Tkachev, E. Skrzypek, B. Murray, V. Latham, M. Sullivan, T. Y. Low, M. A. Mohtar, P. Y. Lee, N. Omar, H. Zhou, M. Ye, M. K. Morris, A. Chi, I. N. Melas, L. G. Alexopoulos, M. L. Guerriero, A. Corrigan, A. Bornot, M. Firth, P. O’Shea, D. Ross-Thriepland, S. Peel, A. Agrotis, R. Ketteler, M. Jost, J. S. Weissman, E. Goncalves, C. Fellmann, B. G. Gowen, P.-C. Lin, J. A. Doudna, J. E. Corn, S. M. B. Nijman, A. E. Enayetallah, D. Ziemek, M. T. Leininger, J. Yang, T. B. Manion, D. E. Mather, W. J. Zavadoski, M. Kuhn, J. L. Treadway, S. A. G. des Etages, E. M. Gibbs, N. Greene, C. M. Steppan, R. Kumar, S. J. Blakemore, C. E. Ellis, E. F. Petricoin, D. Pratt, M. Macoritto, A. L. Matthews, J. J. Loureiro, K. Elliston, R. T. Pillich, V. Rynkov, D. Welker, S. Orchard, S. Kerrien, S. Abbani, B. Aranda, J. Bhate, S. Bidwell, A. Bridge, L. Briganti, F. S. L. Brinkman, G. Cesareni, A. Chatr-aryamontri, E. Chautard, C. Chen, M. Dumousseau, J. Goll, R. E. W. Hancock, L. I. Hannick, I. Jurisica, J. Khadake, D. J. Lynn, U. Mahadevan, L. Perfetto, A. Raghunath, S. Ricard-Blum, B. Roechert, L. Salwinski, V. Stümpflen, M. Tyers, P. Uetz, I. Xenarios, H. Hermjakob, M. D. Wilkinson, M. Dumontier, I. J. J. Aalbersberg, G. Appleton, M. Axton, A. Baak, N. Blomberg, J.-W. Boiten, L. B. da Silva Santos, P. E. Bourne, J. Bouwman, A. J. Brookes, T. Clark, M. Crosas, I. Dillo, O. Dumon, S. Edmunds, C. T. Evelo, R. Finkers, A. J. G. Gray, P. Groth, C. Goble, J. S. Grethe, J. Heringa, P. A. C.’t Hoen, R. Hooft, T. Kuhn, R. Kok, J. Kok, S. J. Lusher, M. E. Martone, A. Mons, A. L. Packer, B. Persson, M. Roos, R. van Schaik, E. Schultes, T. Sengstag, T. Slater, G. Strawn, M. A. Swertz, M. Thompson, J. van der Lei, E. van Mulligen, J. Velterop, A. Waagmeester, P. Wittenburg, K. Wolstencroft, J. Zhao, B. Mons, C. von Mering, L. J. Jensen, B. Snel, S. D. Hooper, M. Krupp, M. Foglierini, N. Jouffre, M. A. Huynen, P. Bork, L. Garcia-Alonso, M. M. Ibrahim, D. Turei, J. Saez-Rodriguez, H. Huang, B. M. Jedynak, J. S. Bader, X. Zhu, M. Gerstein, M. Snyder, K. Luck, D.-K. Kim, L. Lambourne, K. Spirohn, B. E. Begg, W. Bian, R. Brignall, T. Cafarelli, F. J. Campos-Laborie, B. Charloteaux, D. Choi, A. G. Coté, M. Daley, S. Deimling, A. Desbuleux, A. Dricot, M. Gebbia, M. F. Hardy, N. Kishore, J. J. Knapp, I. A. Kovács, I. Lemmens, M. W. Mee, J. C. Mellor, C. Pollis, C. Pons, A. D. Richardson, S. Schlabach, B. Teeking, A. Yadav, M. Babor, D. Balcha, O. Basha, C. Bowman-Colin, S.-F. Chin, S. G. Choi, C. Colabella, G. Coppin, C. D’Amata, D. De Ridder, S. De Rouck, M. Duran-Frigola, H. Ennajdaoui, F. Goebels, L. Goehring, A. Gopal, G. Haddad, E. Hatchi, M. Helmy, Y. Jacob, Y. Kassa, S. Landini, R. Li, N. van Lieshout, A. MacWilliams, D. Markey, J. N. Paulson, S. Rangarajan, J. Rasla, A. Rayhan, T. Rolland, A. San-Miguel, Y. Shen, D. Sheykhkarimli, G. M. Sheynkman, E. Simonovsky, M. Taşan, A. Tejeda, V. Tropepe, J.-C. Twizere, Y. Wang, R. J. Weatheritt, J. Weile, Y. Xia, X. Yang, E. Yeger-Lotem, Q. Zhong, P. Aloy, G. D. Bader, J. De Las Rivas, S. Gaudet, T. Hao, J. Rak, J. Tavernier, D. E. Hill, M. Vidal, F. P. Roth, M. A. Calderwood, S. Bazzani, K. Sriyudthsak, F. Shiraishi, M. Y. Hirai, E. Alm, A. P. Arkin, J. Ma, A. Shojaie, G. Michailidis, S. Chowdhury, R. R. Sarkar, G. Vert, J. Chory, W. A. Haynes, A. Tomczak, P. Khatri, T. Charitou, K. Bryan, A. Brückner, C. Polge, N. Lentze, D. Auerbach, U. Schlattner, B. Tian, C. Zhao, F. Gu, Z. He, R. Krause, M. Cornell, S. G. Oliver, S. Fields, D. Voet, J. G. Voet, A. R. Neves, A. Ramos, M. C. Nunes, M. Kleerebezem, J. Hugenholtz, W. M. de Vos, J. Almeida, H. Santos, S. A. Lambert, A. Jolma, L. F. Campitelli, P. K. Das, M. Albu, X. Chen, J. Taipale, T. R. Hughes, M. T. Weirauch, P. J. Park, A. Blais, B. D. Dynlacht, M. Haque, R. Sarmah, D. K. Bhattacharyya, P. J. Thul, C. Lindskog, R. Barshir, M. Sharon, E. Lerman, B. F. Kirson, I. Hekselman, J. K. Huang, D. E. Carlin, M. K. Yu, W. Zhang, J. F. Kreisberg, P. Tamayo, T. Ideker, D. Yu, M. Kim, G. Xiao, T. H. Hwang, C. H. Wu, N. C. Duarte, S. A. Becker, N. Jamshidi, I. Thiele, M. L. Mo, T. D. Vo, R. Srivas, B. Ø. Palsson, D. Türei, T. Korcsmáros, R. Oughtred, J. Rust, C. Chang, B. Breitkreutz, C. Stark, A. Willems, L. Boucher, G. Leung, N. Kolas, F. Zhang, S. Dolma, J. Coulombe-Huntington, K. Dolinski, E. L. Huttlin, L. Ting, R. J. Bruckner, F. Gebreab, M. P. Gygi, S. Tam, G. Zarraga, G. Colby, K. Baltier, R. Dong, V. Guarani, L. P. Vaites, A. Ordureau, R. Rad, M. Wühr, J. Chick, B. Zhai, D. Kolippakkam, J. Mintseris, R. A. Obar, T. Harris, S. Artavanis-Tsakonas, M. E. Sowa, P. DeCamilli, J. A. Paulo, J. W. Harper, R. Goel, H. C. Harsha, A. Pandey, T. S. K. Prasad, C. S. Greene, A. Krishnan, A. K. Wong, E. Ricciotti, R. A. Zelaya, D. S. Himmelstein, R. Zhang, B. M. Hartmann, E. Zaslavsky, S. C. Sealfon, D. I. Chasman, G. A. FitzGerald, T. Grosser, O. G. Troyanskaya, J. J. O’Shea, D. M. Schwartz, A. V. Villarino, M. Gadina, I. B. McInnes, A. Laurence, S. A. Sam, J. Teel, A. N. Tegge, A. Bharadwaj, T. M. Murali, A. Fabregat, S. Jupe, L. Matthews, K. Sidiropoulos, M. Gillespie, P. Garapati, R. Haw, B. Jassal, F. Korninger, B. May, M. Milacic, C. D. Roca, K. Rothfels, C. Sevilla, V. Shamovsky, S. Shorser, T. Varusai, G. Viteri, J. Weiser, G. Wu, L. Stein, P. D’Eustachio, D. N. Slenter, M. Kutmon, K. Hanspers, A. Riutta, J. Windsor, N. Nunes, J. Mélius, E. Cirillo, S. L. Coort, D. Digles, F. Ehrhart, P. Giesbertz, M. Kalafati, M. Martens, R. Miller, K. Nishida, L. Rieswijk, L. M. T. Eijssen, A. R. Pico, E. L. Willighagen, M. Kanehisa, S. Goto, M. Trupp, T. Altman, C. A. Fulcher, R. Caspi, M. Krummenacker, S. Paley, P. D. Karp, E. G. Cerami, B. E. Gross, E. Demir, I. Rodchenkov, Ö. Babur, N. Anwar, N. Schultz, C. Sander, L. Y. Geer, A. Marchler-Bauer, R. C. Geer, L. Han, C. Liu, W. Shi, S. H. Bryant, S. G. Jantzen, B. J. Sutherland, D. R. Minkley, B. F. Koop, F. Supek, M. Bošnjak, N. Škunca, T. Šmuc, D. V. Klopfenstein, B. S. Pedersen, F. Ramírez, A. Warwick Vesztrocy, A. Naldi, C. J. Mungall, J. M. Yunes, O. Botvinnik, M. Weigel, W. Dampier, C. Dessimoz, P. Flick, H. Tang, D. Domingo-Fernández, S. Mubeen, J. Marín-Llaó, C. T. Hoyt, M. Hofmann-Apitius, A. B. Keenan, M. L. Wojciechowicz, Z. Wang, K. M. Jagodnik, S. L. Jenkins, A. Lachmann, A. Ma’ayan, X. P. Peng, C. Clement, A. Rodina, M. Nieto, J. Du, K. Stegmaier, S. M. Raj, K. N. Maloney, J. Clardy, W. C. Hahn, G. Chiosis, I. Barrett, P. Shannon, T. Sandmann, S. K. Kummerfeld, R. Gentleman, R. Bourgon, M. A. García-Campos, J. Espinal-Enríquez, E. Hernández-Lemus, A. Yuryev, S. Ekins, R. Mathur, D. Rotroff, A. Motsinger-Reif, M. Sirota, A. J. Butte, B. Debrabant, M. E. Ritchie, B. Phipson, D. Wu, C. W. Law, G. K. Smyth, E. Lim, F. Vaillant, M.-L. Asselin-Labat, J. E. Visvader, P. D. Thomas, M. J. Campbell, A. Kejariwal, H. Mi, B. Karlak, R. Daverman, K. Diemer, A. Muruganujan, A. Narechania, E. Y. Chen, C. M. Tan, Y. Kou, Q. Duan, G. V. Meirelles, N. R. Clark, G. Dennis, B. T. Sherman, D. A. Hosack, W. Gao, H. C. Lane, R. A. Lempicki, A. Markiel, O. Ozier, N. S. Baliga, J. T. Wang, D. Ramage, N. Amin, B. Schwikowski, G. Bindea, B. Mlecnik, H. Hackl, P. Charoentong, M. Tosolini, A. Kirilovsky, W.-H. Fridman, F. Pagès, Z. Trajanoski, J. Galon, G. Yu, Q.-Y. He, L.-G. Wang, Y. Han, I. Ihnatova, E. Budinska, F. Li, Y. Qin, X. Bo, Y. Wu, S. Wang, G. Bradley, S. J. Barrett, N. L. Catlett, A. J. Bargnesi, S. Ungerer, T. Seagaran, W. Ladd, K. O. Elliston, S. Jaeger, J. Min, F. Nigsch, M. Camargo, J. Hutz, A. Cornett, S. Cleaver, A. Buckler, J. L. Jenkins, J. H. Woo, Y. Shimoni, W. S. Yang, P. Subramaniam, A. Iyer, P. Nicoletti, M. Rodríguez Martínez, G. López, M. Mattioli, R. Realubit, C. Karan, B. R. Stockwell, M. Bansal, A. Califano, H. Noh, J. E. Shoemaker, R. Gunawan, A. Liu, P. Trairatphisan, E. Gjerga, A. Didangelos, J. Barratt, A. Dugourd, C. Kuppe, M. Sciacovelli, K. B. Emdal, D. B. Bekker-Jensen, J. Kranz, E. M. J. Bindels, A. S. H. Costa, J. V. Olsen, C. Frezza, R. Kramann, A. Dubovenko, Y. Nikolsky, E. Rakhmatulin, T. Nikolskaya, A. Krämer, J. Green, J. Pollard, S. Tugendreich, C. Wiwie, J. Baumbach, R. Röttger, M. R. Karim, O. Beyan, A. Zappa, I. G. Costa, D. Rebholz-Schuhmann, M. Cochez, S. Decker, D. Xu, Y. Tian, F. Pedregosa, G. Varoquaux, A. Gramfort, V. Michel, B. Thirion, O. Grisel, M. Blondel, P. Prettenhofer, R. Weiss, V. Dubourg, J. Vanderplas, A. Passos, D. Cournapeau, M. Mächler, P. Rousseeuw, A. Struyf, M. Hubert, K. Hornik, A. Kassambara, F. Mundt, R. Argelaguet, B. Velten, D. Arnol, S. Dietrich, T. Zenz, J. C. Marioni, F. Buettner, W. Huber, O. Stegle, A. Klami, S. Virtanen, E. Leppäaho, S. Kaski, S. A. Khan, O. P. Kallioniemi, A. Poso, T. Chen, S. Tyagi, D. Bredikhin, Y. Deloro, E. Leppaaho, M. Ammad-ud-din, I. Subramanian, S. Verma, S. Kumar, A. Jere, K. Anamika, R. Chen, X. Liu, S. Jin, J. Lin, J. Liu, J. Vamathevan, D. Clark, P. Czodrowski, I. Dunham, E. Ferran, G. Lee, B. Li, A. Madabhushi, P. Shah, M. Spitzer, S. Zhao, J. Scheiber, M. Glick, J. W. Davies, K. Azzaoui, J. Hamon, L. Urban, S. Whitebread, D. Rogers, M. Hahn, Y. C. Martin, J. L. Kofron, L. M. Traphagen, S. Gao, D. Luo, G. Liu, Z. Xiao, G. Shan, Y. Zhang, W. Zhou, C. Scheeder, M. Boutros, R. P. Sheridan, L. M. Kauvar, D. L. Higgins, H. O. Villar, J. R. Sportsman, A. Engqvist-Goldstein, R. Bukar, K. E. Bauer, H. Dilley, D. M. Rocke, C. Yuan, T. V. Aa, I. Chakroun, J. Simm, A. Arany, Y. Moreau, T. L. Van, J. F. G. Dzib, R. Wuyts, W. Verachtert, M. Wen, Z. Zhang, S. Niu, H. Sha, R. Yang, Y. Yun, H. Lu, A. A. M. Al-Saffar, H. Tao, M. A. Talab, A. Mayr, G. Klambauer, T. Unterthiner, M. Steijaert, D.-A. Clevert, S. Hochreiter, M. C. Robinson, A. A. Lee, I. Cortés-Ciriano, Y. Zhu, T. Brettin, F. Xia, A. Partin, M. Shukla, H. Yoo, Y. A. Evrard, J. H. Doroshow, R. L. Stevens, M. Hofmarcher, E. Rumetshofer, N. Aniceto, A. A. Freitas, T. Ghafourian, N. Bosc, F. Atkinson, E. Felix, A. R. Leach, Y. Saeys, I. Inza, P. Larrañaga, R. Caruana, S. Lawrence, C. L. Giles, Y. E. Wang, G.-Y. Wei, D. Brooks, C. Rudin, M. Walter, P. Wright, A. Bartosik, D. Dolciami, A. Elbasir, N. Fortelny, C. Bock, M. Abadi, P. Barham, Z. Chen, A. Davis, J. Dean, M. Devin, S. Ghemawat, G. Irving, M. Isard, M. Kudlur, J. Levenberg, R. Monga, S. Moore, D. G. Murray, B. Steiner, P. Tucker, V. Vasudevan, P. Warden, M. Wicke, Y. Yu, X. Zheng, A. Paszke, S. Gross, F. Massa, A. Lerer, G. Chanan, T. Killeen, Z. Lin, N. Gimelshein, L. Antiga, A. Desmaison, A. Köpf, E. Yang, Z. DeVito, M. Raison, A. Tejani, S. Chilamkurthy, L. Fang, S. Chintala, P. Zakeri, T. Haber, K. C. Bulusu, L. Kalash, M. A. Firth, Z. Ji, J. Su, H. Wang, D. Huang, X. Zhou, O. Weinreb, T. Amit, M. B. H. Youdim, N. L. Patel-Murray, M. Adam, N. Huynh, B. T. Wassie, P. Milani, E. Fraenkel, J. Vialard, P. Buijnsters, I. Velter, A. Vapirev, M. F. Cuccarese, B. A. Earnshaw, K. Heiser, B. Fogelson, P. F. McLean, H. B. Gordon, K.-R. Skelly, F. L. Weathersby, V. Rodic, I. K. Quigley, E. D. Pastuzyn, B. M. Mendivil, N. H. Lazar, C. A. Brooks, J. Carpenter, B. L. Probst, P. Jacobson, S. W. Glazier, J. Ford, J. D. Jensen, N. D. Campbell, M. A. Statnick, A. S. Low, K. R. Thomas, S. S. Hegde, R. W. Alfa, M. L. Victors, I. S. Haque, M. Kibble, N. Saarinen, F. Iorio, S. Mäkelä, T. Aittokallio, M. Iwata, R. Sawada, H. Iwata, M. Kotera, Y. Yamanishi, E. Dazert, M. Colombi, T. Boldanova, S. Moes, D. Adametz, L. Quagliata, V. Roth, L. Terracciano, M. H. Heim, P. Jenoe, M. N. Hall, D. Carrella, F. Napolitano, R. Rispoli, M. Miglietta, A. Carissimo, L. Cutillo, F. Sirci, F. Gregoretti, D. Di Bernardo, A. Conesa, S. Beck Show less
The elucidation of a compound's Mechanism of Action (MoA) is a challenging task in the drug discovery process, but it is important in order to rationalise phenotypic findings and to anticipate potenti Show more
The elucidation of a compound's Mechanism of Action (MoA) is a challenging task in the drug discovery process, but it is important in order to rationalise phenotypic findings and to anticipate potential side-effects. Bioinformatic approaches, advances in machine learning techniques and the increasing deposition of high-throughput data in public databases have significantly contributed to recent advances in the field, but it is not straightforward to decide which data and methods are most suitable to use in a given case. In this review, we focus on these methods and data and their applications in generating MoA hypotheses for subsequent experimental validation. We discuss compound-specific data such as -omics, cell morphology and bioactivity data, as well as commonly used supplementary prior knowledge such as network and pathway data, and provide information on databases where this data can be accessed. In terms of methodologies, we discuss both well-established methods (connectivity mapping, pathway enrichment) as well as more developing methods (neural networks and multi-omics integration). Finally, we review case studies where the MoA of a compound was successfully suggested from computational analysis by incorporating multiple data modalities and/or methodologies. Our aim for this review is to provide researchers with insights into the benefits and drawbacks of both the data and methods in terms of level of understanding, biases and interpretation – and to highlight future avenues of investigation which we foresee will improve the field of MoA elucidation, including greater public access to -omics data and methodologies which are capable of data integration. Show less
📄 PDF DOI: 10.1039/d1cb00069a
ML review
Zeng Y, Qiu Y, Jiang W +1 more · 2022 · Cancers · MDPI · added 2026-04-20
Zeng Y, Qiu Y, Jiang W, Fu BM Show less
Angiogenesis in tumor growth and progression involves a series of complex changes in the tumor microenvironment. Extracellular vesicles (EVs) are important components of the tumor microenvironment, wh Show more
Angiogenesis in tumor growth and progression involves a series of complex changes in the tumor microenvironment. Extracellular vesicles (EVs) are important components of the tumor microenvironment, which can be classified as exosomes, apoptotic vesicles, and matrix vesicles according to their origins and properties. The EVs that share many common biological properties are important factors for the microenvironmental modification and play a vital role in tumor growth and progression. For example, vascular endothelial growth factor (VEGF) exosomes, which carry VEGF, participate in the tolerance of anti-angiogenic therapy (AAT). The glycocalyx is a mucopolysaccharide structure consisting of glycoproteins, proteoglycans, and glycosaminoglycans. Both endothelial and tumor cells have glycocalyx at their surfaces. Glycocalyx at both cells mediates the secretion and uptake of EVs. On the other hand, many components carried by EVs can modify the glycocalyx, which finally facilitates the development of the tumor microenvironment. In this short review, we first summarize the role of EVs in the development of the tumor microenvironment. Then we review how the glycocalyx is associated with the tumor microenvironment and how it is modulated by the EVs, and finally, we review the role of the glycocalyx in the synthesis, release, and uptake of EVs that affect tumor microenvironments. This review aims to provide a basis for the mechanistic study of AAT and new clues to address the challenges in AAT tolerance, tumor angiogenesis and metastasis. Show less
📄 PDF DOI: 10.3390/cancers14215415
review synthesis
Dai W, Zhang J, Li S +8 more · 2022 · Frontiers in immunology · Frontiers · added 2026-04-20
In recent years, protein arginine methyltransferases (PRMTs) have emerged as new members of a gene expression regulator family in eukaryotes, and are associated with cancer pathogenesis and progressio Show more
In recent years, protein arginine methyltransferases (PRMTs) have emerged as new members of a gene expression regulator family in eukaryotes, and are associated with cancer pathogenesis and progression. Cancer immunotherapy has significantly improved cancer treatment in terms of overall survival and quality of life. Protein arginine methylation is an epigenetic modification function not only in transcription, RNA processing, and signal transduction cascades, but also in many cancer-immunity cycle processes. Arginine methylation is involved in the activation of anti-cancer immunity and the regulation of immunotherapy efficacy. In this review, we summarize the most up-to-date information on regulatory molecular mechanisms and different underlying arginine methylation signaling pathways in innate and adaptive immune responses during cancer. We also outline the potential of PRMT-inhibitors as effective combinatorial treatments with immunotherapy. Show less
📄 PDF DOI: 10.3389/fimmu.2022.865964
amino-acid review
Karas LJ, Wu CH, Das R +1 more · 2021 · Wiley interdisciplinary reviews. Computational molecular science · Wiley · added 2026-04-20
Karas LJ, Wu CH, Das R, Wu JI Show less
Hydrogen bonding principles are at the core of supramolecular design. This overview features a discussion relating molecular structure to hydrogen bond strengths, highlighting the following electronic Show more
Hydrogen bonding principles are at the core of supramolecular design. This overview features a discussion relating molecular structure to hydrogen bond strengths, highlighting the following electronic effects on hydrogen bonding: electronegativity, steric effects, electrostatic effects, π-conjugation, and network cooperativity. Historical developments, along with experimental and computational efforts, leading up to the birth of the hydrogen bond concept, the discovery of nonclassical hydrogen bonds (C-H…O, O-H…π, dihydrogen bonding), and the proposal of hydrogen bond design principles (e.g., secondary electrostatic interactions, resonance-assisted hydrogen bonding, and aromaticity effects) are outlined. Applications of hydrogen bond design principles are presented. Show less
no PDF DOI: 10.1002/wcms.1477
review
Wenping Wu, Jimin Zheng, Zongchao Jia · 2021 · iScience · Elsevier · added 2026-04-20
The mitochondrial uniporter is a Ca2+-selective ion-conducting channel in the inner mitochondrial membrane that is involved in various cellular processes. The components of this uniporter, including t Show more
The mitochondrial uniporter is a Ca2+-selective ion-conducting channel in the inner mitochondrial membrane that is involved in various cellular processes. The components of this uniporter, including the pore-forming membrane subunit MCU and the modulatory subunits MCUb, EMRE, MICU1, and MICU2, have been identified in recent years. Previously, extensive studies revealed various aspects of uniporter activities and proposed multiple regulatory models of mitochondrial Ca2+ uptake. Recently, the individual auxiliary components of the uniporter and its holocomplex have been structurally characterized, providing the first insight into the component structures and their spatial relationship within the context of the uniporter. Here, we review recent uniporter structural studies in an attempt to establish an architectural framework, elucidating the mechanism that governs mitochondrial Ca2+ uptake and regulation, and to address some apparent controversies. This information could facilitate further characterization of mitochondrial Ca2+ permeation and a better understanding of uniporter-related disease conditions. Show less
no PDF DOI: 10.1016/j.isci.2021.102895
mitochondria review
Xuan Wang, Peng An, Zhenglong Gu +2 more · 2021 · International journal of molecular sciences · MDPI · added 2026-04-20
Mitochondria are vital to life and provide biological energy for other organelles and cell physiological processes. On the mitochondrial double layer membrane, there are a variety of channels and tran Show more
Mitochondria are vital to life and provide biological energy for other organelles and cell physiological processes. On the mitochondrial double layer membrane, there are a variety of channels and transporters to transport different metal ions, such as Ca2+, K+, Na+, Mg2+, Zn2+ and Fe2+/Fe3+. Emerging evidence in recent years has shown that the metal ion transport is essential for mitochondrial function and cellular metabolism, including oxidative phosphorylation (OXPHOS), ATP production, mitochondrial integrity, mitochondrial volume, enzyme activity, signal transduction, proliferation and apoptosis. The homeostasis of mitochondrial metal ions plays an important role in maintaining mitochondria and cell functions and regulating multiple diseases. In particular, channels and transporters for transporting mitochondrial metal ions are very critical, which can be used as potential targets to treat neurodegeneration, cardiovascular diseases, cancer, diabetes and other metabolic diseases. This review summarizes the current research on several types of mitochondrial metal ion channels/transporters and their functions in cell metabolism and diseases, providing strong evidence and therapeutic strategies for further insights into related diseases. Show less
no PDF DOI: 10.3390/ijms22147525
mitochondria review
Traba, Javier , Sack, Michael N. , Waldmann, Thomas A. +1 more · 2021 · Frontiers · Frontiers · added 2026-04-20
Constitutive activity of the immune surveillance system detects and kills cancerous cells, although many cancers have developed strageties to avoid detection and to resist their destruction. Cancer im Show more
Constitutive activity of the immune surveillance system detects and kills cancerous cells, although many cancers have developed strageties to avoid detection and to resist their destruction. Cancer immunotherapy entails the manipulation of components of the endogenous immune system as targeted approaches to control and destroy cancer cells. Since one of the major limitations for the antitumor activity of immune cells is the immunosuppressive tumor microenvironment (TME), boosting the immune system to overcome the inhibition provided by the TME is a critical component of oncotherapeutics. In this article, we discuss the main effects of the TME on the metabolism and function of immune cells, and review emerging strategies to potentiate immune cell metabolism to promote antitumor effects either as monotherapeutics or in combination with conventional chemotherapy to optimize cancer management. Show less
📄 PDF DOI: 10.3389/fimmu.2021.657293
anticancer review
2021 · Journal of Inorganic Biochemistry · Elsevier · added 2026-04-20
no PDF DOI: 10.1016/j.jinorgbio.2021.111624
review
Juntaek Oh, Jun Xu, Jenny Chong +1 more · 2021 · Biochimica et biophysica acta. Gene regulatory mechanisms · Elsevier · added 2026-04-20
Transcription elongation by RNA polymerase II (Pol II) is constantly challenged by numerous types of obstacles that lead to transcriptional pausing or stalling. These obstacles include DNA lesions, DN Show more
Transcription elongation by RNA polymerase II (Pol II) is constantly challenged by numerous types of obstacles that lead to transcriptional pausing or stalling. These obstacles include DNA lesions, DNA epigenetic modifications, DNA binding proteins, and non-B form DNA structures. In particular, lesion-induced prolonged transcriptional blockage or stalling leads to genome instability, cellular dysfunction, and cell death. Transcription-coupled nucleotide excision repair (TC-NER) pathway is the first line of defense that detects and repairs these transcription-blocking DNA lesions. In this review, we will first summarize the recent research progress toward understanding the molecular basis of transcriptional pausing and stalling by different kinds of obstacles. We will then discuss new insights into Pol II-mediated lesion recognition and the roles of CSB in TC-NER. Show less
no PDF DOI: 10.1016/j.bbagrm.2020.194659
DNA-binding review
Reinfeld, Bradley I., Rathmell, W. Kimryn, Kim, Tae Kon +1 more · 2021 · Nature Publishing Group · Nature · added 2026-04-20
In 2011, Hanahan and Weinberg added “Deregulating Cellular Energetics” and “Avoiding Immune Destruction” to the six previous hallmarks of cancer. Since this seminal paper, there has been a growing con Show more
In 2011, Hanahan and Weinberg added “Deregulating Cellular Energetics” and “Avoiding Immune Destruction” to the six previous hallmarks of cancer. Since this seminal paper, there has been a growing consensus that these new hallmarks are not mutually exclusive but rather interdependent. The following review summarizes how founding genetic events for tumorigenesis ultimately increase tumor cell glycolysis, which not only supports the metabolic demands of malignancy but also provides an immunoprotective niche, promoting malignant cell proliferation, maintenance and progression. The mechanisms by which altered metabolism contributes to immune impairment are multifactorial: (1) the metabolic demands of proliferating tumor cells and activated immune cells are similar, thus creating a situation where immune cells may be in competition for key nutrients; (2) the metabolic byproducts of aerobic glycolysis directly inhibit antitumor immunity while promoting a regulatory immune phenotype; and (3) the gene programs associated with the upregulation of glycolysis also result in the generation of immunosuppressive cytokines and metabolites. From this perspective, we shed light on important considerations for the development of new classes of agents targeting cancer metabolism. These types of therapies can impair tumor growth but also pose a significant risk of stifling antitumor immunity. Show less
📄 PDF DOI: 10.1038/s41423-021-00727-3
anticancer review
2021 · · Taylor & Francis · added 2026-04-20
Hepatitis A virus (HAV) infections continue to represent a significant disease burden causing approximately 200 million infections, 30 million symptomatic illnesses and 30,000 deaths each year. Effect Show more
Hepatitis A virus (HAV) infections continue to represent a significant disease burden causing approximately 200 million infections, 30 million symptomatic illnesses and 30,000 deaths each year. Effective and safe hepatitis A vaccines have been available since the early 1990s. Initially developed for individual prophylaxis, HAV vaccines are now increasingly used to control hepatitis A in endemic areas. The human enteral HAV is eradicable in principle, however, HAV eradication is currently not being pursued. Inactivated HAV vaccines are safe and, after two doses, elicit seroprotection in healthy children, adolescents, and young adults for an estimated 30-40 years, if not lifelong, with no need for a later second booster. The long-term effects of the single-dose live-attenuated HAV vaccines are less well documented but available data suggest they are safe and provide long-lasting immunity and protection. A universal mass vaccination strategy (UMV) based on two doses of inactivated vaccine is commonly implemented in endemic countries and eliminates clinical hepatitis A disease in toddlers within a few years. Consequently, older age groups also benefit due to the herd protection effects. Single-dose UMV programs have shown promising outcomes but need to be monitored for many more years in order to document an effective immune memory persistence. In non-endemic countries, prevention efforts need to focus on 'new' risk groups, such as men having sex with men, prisoners, the homeless, and families visiting friends and relatives in endemic countries. This narrative review presents the current evidence regarding the immunological and epidemiological long-term effects of the hepatitis A vaccination and finally discusses emerging issues and areas for research. Show less
📄 PDF DOI: 10.1080/21645515.2020.1819742
review
Haiwei Wang, Bin Fang, Bo Peng +8 more · 2021 · Frontiers in chemistry · Frontiers · added 2026-04-20
Mitochondria are vital subcellular organelles that generate most cellular chemical energy, regulate cell metabolism and maintain cell function. Mitochondrial dysfunction is directly linked to numerous Show more
Mitochondria are vital subcellular organelles that generate most cellular chemical energy, regulate cell metabolism and maintain cell function. Mitochondrial dysfunction is directly linked to numerous diseases including neurodegenerative disorders, diabetes, thyroid squamous disease, cancer and septicemia. Thus, the design of specific mitochondria-targeting molecules and the realization of real-time acquisition of mitochondrial activity are powerful tools in the study and treatment of mitochondria dysfunction in related diseases. Recent advances in mitochondria-targeting agents have led to several important mitochondria chemical probes that offer the opportunity for selective targeting molecules, novel biological applications and therapeutic strategies. This review details the structural and physiological functional characteristics of mitochondria, and comprehensively summarizes and classifies mitochondria-targeting agents. In addition, their pros and cons and their related chemical biological applications are discussed. Finally, the potential biomedical applications of these agents are briefly prospected. Show less
📄 PDF DOI: 10.3389/fchem.2021.683220
mitochondria review
Emiliano Panieri, Luciano Saso · 2021 · Antioxidants & redox signaling · added 2026-04-20
Significance: The nuclear factor erythroid 2-related factor 2/Kelch-like ECH-associated protein 1 (NRF2/KEAP1) pathway is a crucial and highly conserved defensive system that is required to maintain o Show more
Significance: The nuclear factor erythroid 2-related factor 2/Kelch-like ECH-associated protein 1 (NRF2/KEAP1) pathway is a crucial and highly conserved defensive system that is required to maintain or restore the intracellular homeostasis in response to oxidative, electrophilic, and other types of stress conditions. The tight control of NRF2 function is maintained by a complex network of biological interactions between positive and negative regulators that ultimately ensure context-specific activation, culminating in the NRF2-driven transcription of cytoprotective genes. Recent Advances: Recent studies indicate that deregulated NRF2 activation is a frequent event in malignant tumors, wherein it is associated with metabolic reprogramming, increased antioxidant capacity, chemoresistance, and poor clinical outcome. On the other hand, the growing interest in the modulation of the cancer cells' redox balance identified NRF2 as an ideal therapeutic target. Critical Issues: For this reason, many efforts have been made to identify potent and selective NRF2 inhibitors that might be used as single agents or adjuvants of anticancer drugs with redox disrupting properties. Despite the lack of specific NRF2 inhibitors still represents a major clinical hurdle, the researchers have exploited alternative strategies to disrupt NRF2 signaling at different levels of its biological activation. Future Directions: Given its dualistic role in tumor initiation and progression, the identification of the appropriate biological context of NRF2 activation and the specific clinicopathological features of patients cohorts wherein its inactivation is expected to have clinical benefits, will represent a major goal in the field of cancer research. In this review, we will briefly describe the structure and function of the NRF2/ KEAP1 system and some of the most promising NRF2 inhibitors, with a particular emphasis on natural compounds and drug repurposing. Antioxid. Redox Signal. 34, 1428-1483. Show less
no PDF DOI: 10.1089/ars.2020.8146
amino-acid anticancer review
Carracedo-Reboredo P, Liñares-Blanco J, Rodríguez-Fernández N +6 more · 2021 · Computational and Structural Biotechnology Journal · Elsevier · added 2026-04-20
Drug discovery aims at finding new compounds with specific chemical properties for the treatment of diseases. In the last years, the approach used in this search presents an important component in com Show more
Drug discovery aims at finding new compounds with specific chemical properties for the treatment of diseases. In the last years, the approach used in this search presents an important component in computer science with the skyrocketing of machine learning techniques due to its democratization. With the objectives set by the Precision Medicine initiative and the new challenges generated, it is necessary to establish robust, standard and reproducible computational methodologies to achieve the objectives set. Currently, predictive models based on Machine Learning have gained great importance in the step prior to preclinical studies. This stage manages to drastically reduce costs and research times in the discovery of new drugs. This review article focuses on how these new methodologies are being used in recent years of research. Analyzing the state of the art in this field will give us an idea of where cheminformatics will be developed in the short term, the limitations it presents and the positive results it has achieved. This review will focus mainly on the methods used to model the molecular data, as well as the biological problems addressed and the Machine Learning algorithms used for drug discovery in recent years. Show less
📄 PDF DOI: 10.1016/j.csbj.2021.08.011
ML review
Yong-Xing Li, Shu-Fang Cui, Wei Meng +2 more · 2021 · Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · added 2026-04-20
Mitochondria are important organelles that present extensively in cells, serving diverse functions. In addition to controlling cell energy production and metabolism, mitochondria are also involved in Show more
Mitochondria are important organelles that present extensively in cells, serving diverse functions. In addition to controlling cell energy production and metabolism, mitochondria are also involved in various biological processes, including anti-infection, apoptosis, and autophagy. Harmful stimuli from external environment or those generated by the cells themselves can damage mitochondria and cause mitochondrial stress response, during which the mitochondrial matrix containing mitochondrial DNA (mtDNA) can leak into the cytoplasm. Cytoplasmic mtDNA, acting as a damage-associated molecular pattern (DAMP), can activate a panel of DNA sensors and elicit innate immune response in organisms. Cyclic GMP-AMP synthase (cGAS), a key intracellular DNA sensor, can catalyze the conversion of GTP and ATP to cyclic GMP-AMP (2'3'-cGAMP), which serves as second messenger to bind and activate stimulator of interferon gene (STING), an endoplasmic adaptor protein. Beyond its critical roles in anti-microbial immunity, cGAS-STING pathway also serves important functions in many pathological and physiological processes such as autoimmunity, tumor and senescence. In this review, we focus on how the mtDNA released during mitochonrial stress response activates the cGAS-STING innate immune signaling pathway and the associated diseases, in order to help promote basic research about the role of mitochondria in innate immunity and provide new strategies for developing mitochondria-targeting drugs. Show less
no PDF DOI: 10.12182/20210560501
amino-acid mitochondria review sensor
Angela Casini, Ramon Vilar · 2021 · Current opinion in chemical biology · Elsevier · added 2026-04-20
no PDF DOI: 10.1016/j.cbpa.2021.04.007
review
2021 · DNA Repair · Elsevier · added 2026-04-20
no PDF DOI: 10.1016/j.dnarep.2021.103143
review
Emily A Erdmann, Ananya Mahapatra, Priyanka Mukherjee +2 more · 2021 · Critical reviews in biochemistry and molecular biology · Taylor & Francis · added 2026-04-20
Adenosine deaminases that act on RNA (ADARs) are present in all animals and function to both bind double-stranded RNA (dsRNA) and catalyze the deamination of adenosine (A) to inosine (I). As inosine i Show more
Adenosine deaminases that act on RNA (ADARs) are present in all animals and function to both bind double-stranded RNA (dsRNA) and catalyze the deamination of adenosine (A) to inosine (I). As inosine is a biological mimic of guanosine, deamination by ADARs changes the genetic information in the RNA sequence and is commonly referred to as RNA editing. Millions of A-to-I editing events have been reported for metazoan transcriptomes, indicating that RNA editing is a widespread mechanism used to generate molecular and phenotypic diversity. Loss of ADARs results in lethality in mice and behavioral phenotypes in worm and fly model systems. Furthermore, alterations in RNA editing occur in over 35 human pathologies, including several neurological disorders, metabolic diseases, and cancers. In this review, a basic introduction to ADAR structure and target recognition will be provided before summarizing how ADARs affect the fate of cellular RNAs and how researchers are using this knowledge to engineer ADARs for personalized medicine. In addition, we will highlight the important roles of ADARs and RNA editing in innate immunity and cancer biology. Show less
📄 PDF DOI: 10.1080/10409238.2020.1856768
review
Yunxiang Zhou, Lihong Liu, Sifeng Tao +5 more · 2021 · Pharmacological research · Elsevier · added 2026-04-20
Parthanatos is a PARP1-dependent, caspase-independent, cell-death pathway that is distinct from apoptosis, necrosis, or other known forms of cell death. Parthanatos is a multistep pathway that plays a Show more
Parthanatos is a PARP1-dependent, caspase-independent, cell-death pathway that is distinct from apoptosis, necrosis, or other known forms of cell death. Parthanatos is a multistep pathway that plays a pivotal role in tumorigenesis. There are many molecules in the parthanatos cascade that can be exploited to create therapeutic interventions for cancer management, including PARP1, PARG, ARH3, AIF, and MIF. These critical molecules are involved in tumor cell proliferation, progression, invasion, and metastasis. Therefore, these molecular signals in the parthanatos cascade represent promising therapeutic targets for cancer therapy. In addition, intimate interactions occur between parthanatos and other forms of cancer cell death, such as apoptosis and autophagy. Thus, co-targeting a combination of parthanatos and other death pathways may further provide a new avenue for cancer precision treatment. In this review, we elaborate on the signaling pathways of canonical parthanatos and briefly introduce the non-canonical parthanatos. We also shed light on the role parthanatos and its associated components play in tumorigenesis, particularly with respect to the aforementioned five molecules, and discuss the promise targeted therapy of parthanatos and its associated components holds for cancer therapy. Show less
no PDF DOI: 10.1016/j.phrs.2020.105299
Co review
Huang, Dongqing, Savage, Sara R., Calinawan, Anna P. +6 more · 2021 · Nature Publishing Group · Nature · added 2026-04-20
Platinum-based chemotherapy, including cisplatin, carboplatin, and oxaliplatin, is prescribed to 10-20% of all cancer patients. Unfortunately, platinum resistance develops in a significant number of p Show more
Platinum-based chemotherapy, including cisplatin, carboplatin, and oxaliplatin, is prescribed to 10-20% of all cancer patients. Unfortunately, platinum resistance develops in a significant number of patients and is a determinant of clinical outcome. Extensive research has been conducted to understand and overcome platinum resistance, and mechanisms of resistance can be categorized into several broad biological processes, including (1) regulation of drug entry, exit, accumulation, sequestration, and detoxification, (2) enhanced repair and tolerance of platinum-induced DNA damage, (3) alterations in cell survival pathways, (4) alterations in pleiotropic processes and pathways, and (5) changes in the tumor microenvironment. As a resource to the cancer research community, we provide a comprehensive overview accompanied by a manually curated database of the >900 genes/proteins that have been associated with platinum resistance over the last 30 years of literature. The database is annotated with possible pathways through which the curated genes are related to platinum resistance, types of evidence, and hyperlinks to literature sources. The searchable, downloadable database is available online at http://ptrc-ddr.cptac-data-view.org . Show less
📄 PDF DOI: 10.1038/s41388-021-02055-2
DNA-binding Pt review